查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1621575

尿激酶市場：按類型、劑量強度、適應症和應用分類 - 全球預測 2025-2030

Urokinase Market by Type (Urokinase Powder, Urokinase Solution), Dose Strength (250000 Unit, 5000 Unit), Indication, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年尿激酶市值為17.6億美元，預計到2024年將達到18.5億美元，複合年成長率為5.30%，預計到2030年將達到25.2億美元。

尿激酶是一種用於溶解血栓的酶，在溶栓治療中發揮至關重要的作用，特別是對於心肌梗塞和肺動脈栓塞。尿激酶的市場由其在急診醫學中的應用決定，其中快速溶栓提供了關鍵的挽救生命的治療。對尿激酶的需求源於其在治療急性血栓性疾病的有效性，全球心血管疾病發生率的上升推動了需求的成長。該研究涵蓋了醫院、專科診所以及用於治療和實驗的實驗室。該市場正受到人口老化、醫療保健支出增加以及生物技術進步帶來的產品改進等因素的影響。然而，高昂的治療成本、嚴格的監管要求以及來自組織胞漿素原原活化劑（tPA）等替代療法的競爭構成了成長的主要障礙。

主要市場統計
基準年[2023] 17.6億美元
預計年份 [2024] 18.5億美元
預測年份 [2030] 25.2億美元
複合年成長率（%） 5.30%

目前的發展機會在於將尿激酶的應用擴展到新的治療領域，由於意識的提高和醫療基礎設施的改善而在發展中地區增加使用，以及生物製造的潛在發展以降低成本。為了利用這些機會，企業必須注重策略夥伴關係和研發投資，以使尿激酶的應用多樣化，同時確保符合監管標準。風險包括潛在的副作用、生物相似藥的出現以及原料供應的波動，這對市場滲透構成了挑戰。

創新的重點是提高配方的特異性和功效、個人化藥物以實現個人化溶栓治療，以及改進給藥機制。此外，對大規模臨床試驗的投資可以深入了解尿激酶的更廣泛應用，並提供可以對監管機構和付款人產生有利影響的有價值的資料。尿激酶市場是充滿活力的，其特點是競爭格局，持續的技術創新以及對具有成本效益的生產和廣泛應用的戰略重點是持續成長和應對市場挑戰的關鍵。

市場動態：揭示快速發展的尿激酶市場的關鍵市場洞察

尿激酶市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球肺動脈栓塞和冠狀動脈栓塞的盛行率不斷上升==。
    • 政府對尿激酶藥物的支持性核准
  • 市場限制因素
    • 藥物開發成本上升和替代藥物的供應
  • 市場機會
    • 持續研發提高尿激酶的適用性
    • 採用先進的藥物傳遞系統增強尿激酶的治療效果
  • 市場挑戰
    • 與尿激酶藥物相關的副作用

波特的五力：駕馭尿激酶市場的策略工具

波特的五力框架是了解尿激酶市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解尿激酶市場的外部影響

外部宏觀環境因素在塑造尿激酶市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解尿激酶市場競爭狀況

對尿激酶市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣尿激酶市場供應商績效評估

FPNV定位矩陣是評估尿激酶市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了尿激酶市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，尿激酶市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球肺動脈栓塞和冠狀動脈栓塞的發生率正在增加 =
      • 政府核准尿激酶藥物
    • 抑制因素
      • 藥物開發高成本且替代品可用性高
    • 機會
      • 持續研發提高尿激酶的適用性
      • 採用先進的藥物傳遞系統來增強基於尿激酶的療法的功效
    • 任務
      • 與尿激酶藥物相關的副作用
  • 市場區隔分析
    • 類型：尿激酶粉因其保存期限長而備受青睞
    • 應用：擴大尿激酶作為重要治療藥物在醫院的應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章尿激酶市場：依類型

  • 尿激酶粉
  • 尿激酶溶液

第7章以劑量強度分類的尿激酶市場

  • 25萬台
  • 5000 單位

第8章尿激酶市場適應症

  • 導管間隙
  • 冠狀動脈栓塞
  • 深層靜脈栓塞症
  • 肺動脈栓塞

第9章尿激酶市場：依應用分類

  • 醫院
  • 調查機構
  • 專科診所

第10章美洲尿激酶市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區尿激酶市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲尿激酶市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 策略夥伴關係帶回 Kinlytic：溶栓治療的突破
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • BBT Biotech GmbH
  • Cerbios-Pharma SA
  • Echelon Biosciences
  • Ilex Life Sciences LLC
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Aidea Pharmaceutical Co., Ltd
  • Jiangxi Haoran Bio-pharma Co., Ltd.
  • Kraeber & Co GmbH
  • Merck KGaA
  • Microbix Biosystems Inc.
  • Midas Pharma GmbH
  • Pfizer Inc.
  • Syner-Med Pharmaceuticals
  • Taj Pharmaceuticals Ltd.
  • Thermo Fisher Scientific Inc.
  • VWR International, LLC
  • Wanhua Biochem Products Co. Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-0355054AC506

The Urokinase Market was valued at USD 1.76 billion in 2023, expected to reach USD 1.85 billion in 2024, and is projected to grow at a CAGR of 5.30%, to USD 2.52 billion by 2030.

Urokinase, an enzyme used to dissolve blood clots, plays a pivotal role in thrombolytic therapy, particularly in conditions such as myocardial infarction and pulmonary embolism. The market for urokinase is defined by its application in emergency medicine, providing life-saving interventions where rapid clot dissolution is crucial. Necessity arises from its effectiveness in treating acute thrombotic conditions, with a growing demand influenced by the rising incidence of cardiovascular diseases globally. The scope of urokinase extends to hospitals, specialty clinics, and research laboratories where it's used both therapeutically and experimentally. The market is influenced by factors such as an aging population, increasing healthcare expenditure, and advancements in biotechnology driving product enhancement. However, significant growth barriers include high therapy costs, stringent regulatory requirements, and competition from alternative therapies like tissue plasminogen activator (tPA).

KEY MARKET STATISTICS
Base Year [2023] USD 1.76 billion
Estimated Year [2024] USD 1.85 billion
Forecast Year [2030] USD 2.52 billion
CAGR (%) 5.30%

Current opportunities lie in expanding urokinase's application into novel therapeutic areas, increased use in developing regions due to heightened awareness and healthcare infrastructure improvements, and potential development in bio-manufacturing to reduce costs. To capitalize on these opportunities, companies should focus on strategic partnerships and R&D investments to diversify urokinase applications while ensuring compliance with regulatory standards. Risks involve possible side effects, the emergence of biosimilars, and fluctuations in raw material availability, posing challenges to market penetration.

Innovation could focus on enhancing the specificity and efficacy of urokinase formulations, personalized medicine approaches to tailored thrombolytic therapy, and improved delivery mechanisms. Additionally, investments in large-scale clinical trials could provide insights into broader applications of urokinase, contributing valuable data that may favorably influence regulators and payers. The urokinase market is dynamic, characterized by a competitive landscape where continuous innovation and strategic leanings towards cost-effective production and wide-scale application are key for sustainable growth and resilience against market challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urokinase Market

The Urokinase Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of pulmonary embolism and coronary artery thrombosis worldwide=
    • Supportive government approvals for urokinase-based medications
  • Market Restraints
    • High costs of drug development and availability of alternatives
  • Market Opportunities
    • Ongoing research and development to improve the applicability of urokinase
    • Adoption of advanced drug delivery systems to enhance the effectiveness of urokinase-based treatments
  • Market Challenges
    • Side effects associated with urokinase-based drugs

Porter's Five Forces: A Strategic Tool for Navigating the Urokinase Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urokinase Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urokinase Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urokinase Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urokinase Market

A detailed market share analysis in the Urokinase Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urokinase Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urokinase Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Urokinase Market

A strategic analysis of the Urokinase Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Urokinase Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BBT Biotech GmbH, Cerbios-Pharma SA, Echelon Biosciences, Ilex Life Sciences LLC, JCR Pharmaceuticals Co., Ltd., Jiangsu Aidea Pharmaceutical Co., Ltd, Jiangxi Haoran Bio-pharma Co., Ltd., Kraeber & Co GmbH, Merck KGaA, Microbix Biosystems Inc., Midas Pharma GmbH, Pfizer Inc., Syner-Med Pharmaceuticals, Taj Pharmaceuticals Ltd., Thermo Fisher Scientific Inc., VWR International, LLC, Wanhua Biochem Products Co. Ltd., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Urokinase Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Urokinase Powder and Urokinase Solution.
  • Based on Dose Strength, market is studied across 250000 Unit and 5000 Unit.
  • Based on Indication, market is studied across Catheter Clearance, Coronary Artery Thrombosis, Deep Vein Thrombosis, and Pulmonary Embolism.
  • Based on Application, market is studied across Hospital, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of pulmonary embolism and coronary artery thrombosis worldwide=
      • 5.1.1.2. Supportive government approvals for urokinase-based medications
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of drug development and availability of alternatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development to improve the applicability of urokinase
      • 5.1.3.2. Adoption of advanced drug delivery systems to enhance the effectiveness of urokinase-based treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with urokinase-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Significant preference towards urokinase powder due to superior shelf life
    • 5.2.2. Application: Expanding application of urokinase in hospitals as a pivotal therapeutic agent
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Urokinase Market, by Type

  • 6.1. Introduction
  • 6.2. Urokinase Powder
  • 6.3. Urokinase Solution

7. Urokinase Market, by Dose Strength

  • 7.1. Introduction
  • 7.2. 250000 Unit
  • 7.3. 5000 Unit

8. Urokinase Market, by Indication

  • 8.1. Introduction
  • 8.2. Catheter Clearance
  • 8.3. Coronary Artery Thrombosis
  • 8.4. Deep Vein Thrombosis
  • 8.5. Pulmonary Embolism

9. Urokinase Market, by Application

  • 9.1. Introduction
  • 9.2. Hospital
  • 9.3. Research Institutions
  • 9.4. Specialty Clinics

10. Americas Urokinase Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Urokinase Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Urokinase Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Strategic Alliance Revives Kinlytic: A Milestone in Thrombolytic Therapy
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. BBT Biotech GmbH
  • 3. Cerbios-Pharma SA
  • 4. Echelon Biosciences
  • 5. Ilex Life Sciences LLC
  • 6. JCR Pharmaceuticals Co., Ltd.
  • 7. Jiangsu Aidea Pharmaceutical Co., Ltd
  • 8. Jiangxi Haoran Bio-pharma Co., Ltd.
  • 9. Kraeber & Co GmbH
  • 10. Merck KGaA
  • 11. Microbix Biosystems Inc.
  • 12. Midas Pharma GmbH
  • 13. Pfizer Inc.
  • 14. Syner-Med Pharmaceuticals
  • 15. Taj Pharmaceuticals Ltd.
  • 16. Thermo Fisher Scientific Inc.
  • 17. VWR International, LLC
  • 18. Wanhua Biochem Products Co. Ltd.
  • 19. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. UROKINASE MARKET RESEARCH PROCESS
  • FIGURE 2. UROKINASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL UROKINASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL UROKINASE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL UROKINASE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES UROKINASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES UROKINASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UROKINASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. UROKINASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. UROKINASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL UROKINASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. UROKINASE MARKET DYNAMICS
  • TABLE 7. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL UROKINASE MARKET SIZE, BY UROKINASE POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL UROKINASE MARKET SIZE, BY UROKINASE SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL UROKINASE MARKET SIZE, BY 250000 UNIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL UROKINASE MARKET SIZE, BY 5000 UNIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL UROKINASE MARKET SIZE, BY CATHETER CLEARANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL UROKINASE MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL UROKINASE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS UROKINASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES UROKINASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UROKINASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. UROKINASE MARKET, FPNV POSITIONING MATRIX, 2023